Triglav Skladi D.O.O. Invests $1.09 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Triglav Skladi D.O.O. bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 16,500 shares of the biotechnology company's stock, valued at approximately $1,085,000.

A number of other hedge funds have also recently modified their holdings of BMRN. Merit Financial Group LLC acquired a new stake in BioMarin Pharmaceutical during the 4th quarter worth $317,000. Swedbank AB grew its position in BioMarin Pharmaceutical by 11.2% during the 4th quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock worth $28,403,000 after purchasing an additional 43,593 shares during the last quarter. Rhumbline Advisers grew its position in BioMarin Pharmaceutical by 2.0% during the 4th quarter. Rhumbline Advisers now owns 556,255 shares of the biotechnology company's stock worth $36,563,000 after purchasing an additional 11,025 shares during the last quarter. Mediolanum International Funds Ltd purchased a new position in BioMarin Pharmaceutical during the 4th quarter worth $1,237,000. Finally, Empowered Funds LLC purchased a new position in BioMarin Pharmaceutical during the 4th quarter worth $257,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN traded down $0.46 during midday trading on Friday, hitting $57.55. The company had a trading volume of 1,732,309 shares, compared to its average volume of 1,867,263. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a twelve month low of $52.93 and a twelve month high of $94.85. The business has a 50-day simple moving average of $62.42 and a two-hundred day simple moving average of $64.80. The firm has a market capitalization of $11.04 billion, a price-to-earnings ratio of 26.16, a price-to-earnings-growth ratio of 0.61 and a beta of 0.27.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $90.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Scotiabank raised their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research report on Thursday, February 20th. Bank of America raised their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Wall Street Zen raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Finally, The Goldman Sachs Group dropped their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a research note on Monday, May 5th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $93.45.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the transaction, the chief accounting officer now owns 14,173 shares in the company, valued at approximately $840,600.63. The trade was a 11.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 4,698 shares of company stock worth $308,172. Insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.